Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
MD 101 / MaimoniDex RA
NCT03503968 / 2017-000440-18: TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms	Terminated	1/2	9	Europe	MDG1011, Investigator Choice therapy	Medigene AG	Safety, Tolerability, Feasibility, Treatment Efficacy	06/22	07/22
ACTRN12623001217695: An open, phase Ia safety and dosing clinical trial evaluating IMD-101 in participants with advanced solid tumours.	Not yet recruiting	1	30			Catalysis Therapeutics Pty Ltd, Catalysis Therapeutics Pty Ltd	Advanced malignant solid tumours

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
MD 101 / MaimoniDex RA
NCT03503968 / 2017-000440-18: TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms	Terminated	1/2	9	Europe	MDG1011, Investigator Choice therapy	Medigene AG	Safety, Tolerability, Feasibility, Treatment Efficacy	06/22	07/22
ACTRN12623001217695: An open, phase Ia safety and dosing clinical trial evaluating IMD-101 in participants with advanced solid tumours.	Not yet recruiting	1	30			Catalysis Therapeutics Pty Ltd, Catalysis Therapeutics Pty Ltd	Advanced malignant solid tumours